vs

Side-by-side financial comparison of CORCEPT THERAPEUTICS INC (CORT) and IMMERSION CORP (IMMR). Click either name above to swap in a different company.

IMMERSION CORP is the larger business by last-quarter revenue ($372.9M vs $202.1M, roughly 1.8× CORCEPT THERAPEUTICS INC). CORCEPT THERAPEUTICS INC runs the higher net margin — 12.0% vs -4.6%, a 16.6% gap on every dollar of revenue. On growth, IMMERSION CORP posted the faster year-over-year revenue change (750.4% vs 11.1%). Over the past eight quarters, IMMERSION CORP's revenue compounded faster (537.9% CAGR vs 17.3%).

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

Immersion Corporation is an Aventura, Florida based developer and licensor of touch feedback technology, also known as haptic technology. Immersion Corporation has been accused of being a patent troll. Founded in 1993 by Louis Rosenberg, it is currently headed by lawyer Francis Jose, who serves as both chief executive officer and general counsel.

CORT vs IMMR — Head-to-Head

Bigger by revenue
IMMR
IMMR
1.8× larger
IMMR
$372.9M
$202.1M
CORT
Growing faster (revenue YoY)
IMMR
IMMR
+739.3% gap
IMMR
750.4%
11.1%
CORT
Higher net margin
CORT
CORT
16.6% more per $
CORT
12.0%
-4.6%
IMMR
Faster 2-yr revenue CAGR
IMMR
IMMR
Annualised
IMMR
537.9%
17.3%
CORT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CORT
CORT
IMMR
IMMR
Revenue
$202.1M
$372.9M
Net Profit
$24.3M
$-17.0M
Gross Margin
98.7%
Operating Margin
2.2%
-2.8%
Net Margin
12.0%
-4.6%
Revenue YoY
11.1%
750.4%
Net Profit YoY
-21.0%
-191.3%
EPS (diluted)
$0.20
$-0.57

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CORT
CORT
IMMR
IMMR
Q4 25
$202.1M
Q3 25
$207.6M
Q2 25
$194.4M
$372.9M
Q1 25
$157.2M
$471.3M
Q4 24
$181.9M
$616.2M
Q3 24
$182.5M
Q2 24
$163.8M
$95.5M
Q1 24
$146.8M
$43.8M
Net Profit
CORT
CORT
IMMR
IMMR
Q4 25
$24.3M
Q3 25
$19.7M
Q2 25
$35.1M
$-17.0M
Q1 25
$20.5M
$24.1M
Q4 24
$30.7M
$30.8M
Q3 24
$47.2M
Q2 24
$35.5M
$26.4M
Q1 24
$27.8M
$18.7M
Gross Margin
CORT
CORT
IMMR
IMMR
Q4 25
98.7%
Q3 25
97.8%
Q2 25
98.2%
Q1 25
98.5%
Q4 24
98.4%
Q3 24
98.4%
Q2 24
98.5%
Q1 24
98.3%
Operating Margin
CORT
CORT
IMMR
IMMR
Q4 25
2.2%
Q3 25
4.9%
Q2 25
13.7%
-2.8%
Q1 25
2.2%
7.5%
Q4 24
13.9%
11.4%
Q3 24
25.5%
Q2 24
21.7%
23.7%
Q1 24
20.1%
37.9%
Net Margin
CORT
CORT
IMMR
IMMR
Q4 25
12.0%
Q3 25
9.5%
Q2 25
18.1%
-4.6%
Q1 25
13.1%
5.1%
Q4 24
16.9%
5.0%
Q3 24
25.9%
Q2 24
21.7%
27.7%
Q1 24
18.9%
42.5%
EPS (diluted)
CORT
CORT
IMMR
IMMR
Q4 25
$0.20
Q3 25
$0.16
Q2 25
$0.29
$-0.57
Q1 25
$0.17
$0.73
Q4 24
$0.25
$0.93
Q3 24
$0.41
Q2 24
$0.32
$0.81
Q1 24
$0.25
$0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CORT
CORT
IMMR
IMMR
Cash + ST InvestmentsLiquidity on hand
$372.2M
$161.4M
Total DebtLower is stronger
$103.1M
Stockholders' EquityBook value
$647.8M
$298.1M
Total Assets
$836.7M
$1.1B
Debt / EquityLower = less leverage
0.35×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CORT
CORT
IMMR
IMMR
Q4 25
$372.2M
Q3 25
$421.7M
Q2 25
$342.2M
$161.4M
Q1 25
$322.8M
$153.9M
Q4 24
$383.3M
$159.3M
Q3 24
$380.3M
Q2 24
$473.2M
$133.4M
Q1 24
$410.8M
$179.1M
Total Debt
CORT
CORT
IMMR
IMMR
Q4 25
Q3 25
Q2 25
$103.1M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CORT
CORT
IMMR
IMMR
Q4 25
$647.8M
Q3 25
$631.9M
Q2 25
$635.8M
$298.1M
Q1 25
$683.3M
$317.9M
Q4 24
$679.6M
$305.5M
Q3 24
$638.8M
Q2 24
$596.2M
$273.4M
Q1 24
$547.9M
$201.5M
Total Assets
CORT
CORT
IMMR
IMMR
Q4 25
$836.7M
Q3 25
$823.6M
Q2 25
$801.7M
$1.1B
Q1 25
$846.5M
$1.4B
Q4 24
$840.6M
$1.4B
Q3 24
$784.3M
Q2 24
$714.6M
$1.2B
Q1 24
$655.9M
$244.7M
Debt / Equity
CORT
CORT
IMMR
IMMR
Q4 25
Q3 25
Q2 25
0.35×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CORT
CORT
IMMR
IMMR
Operating Cash FlowLast quarter
$38.4M
Free Cash FlowOCF − Capex
$38.4M
FCF MarginFCF / Revenue
19.0%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
1.58×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CORT
CORT
IMMR
IMMR
Q4 25
$38.4M
Q3 25
$54.5M
Q2 25
$43.9M
Q1 25
$5.1M
$-43.7M
Q4 24
$59.3M
Q3 24
$73.8M
Q2 24
$41.2M
$-85.9M
Q1 24
$23.8M
$29.9M
Free Cash Flow
CORT
CORT
IMMR
IMMR
Q4 25
$38.4M
Q3 25
Q2 25
$43.9M
Q1 25
$5.0M
$-46.2M
Q4 24
$59.2M
Q3 24
$72.2M
Q2 24
$40.8M
Q1 24
FCF Margin
CORT
CORT
IMMR
IMMR
Q4 25
19.0%
Q3 25
Q2 25
22.6%
Q1 25
3.2%
-9.8%
Q4 24
32.5%
Q3 24
39.5%
Q2 24
24.9%
Q1 24
Capex Intensity
CORT
CORT
IMMR
IMMR
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.1%
0.5%
Q4 24
0.1%
Q3 24
0.9%
Q2 24
0.3%
Q1 24
0.0%
Cash Conversion
CORT
CORT
IMMR
IMMR
Q4 25
1.58×
Q3 25
2.77×
Q2 25
1.25×
Q1 25
0.25×
-1.82×
Q4 24
1.93×
Q3 24
1.56×
Q2 24
1.16×
-3.25×
Q1 24
0.86×
1.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CORT
CORT

Segment breakdown not available.

IMMR
IMMR

Course Material Sale$150.9M40%
General Merchandise Sale$138.0M37%
Rental Services$51.8M14%
Services And Other Revenue$25.6M7%
Per Unit Royalties$1.8M0%

Related Comparisons